CD38单抗难治性多发性骨髓瘤患者的结局
该研究分析了14家学术中心275例对CD38单抗难治的多发性骨髓瘤患者,中位总生存期自难治起点为8.6个月,五药难治者仅5.6个月,后续治疗总缓解率31%,中位无进展生存期3.4个月,提示该人群预后差。
要点
- CD38单抗难治后中位总生存期8.6个月,五药难治者5.6个月。
- 后续首个方案总缓解率31%,中位无进展生存期3.4个月。
- 卡非佐米联合烷化剂方案中位无进展生存期5.7个月。
核心结论
- 对CD38单抗难治的多发性骨髓瘤患者预后差,本研究为该人群新疗法试验提供基准。
研究设计与样本
- 研究分析了14家学术中心275例对CD38单抗难治的多发性骨髓瘤患者。
主要发现
- 从多发性骨髓瘤诊断至CD38单抗难治的中位间隔为50.1个月。
- 自难治起点中位总生存期全队列为8.6个月(95%CI 7.5-9.9)。
- 未同时对免疫调节剂和蛋白酶体抑制剂难治者中位总生存期11.2个月,五药难治者5.6个月。
- 难治起点后249例(90%)接受至少一种后续治疗方案,首个方案总缓解率31%,中位无进展生存期3.4个月,中位总生存期9.3个月。
- 卡非佐米联合烷化剂中位无进展生存期5.7个月,达雷妥尤单抗联合免疫调节剂中位无进展生存期4.5个月。
关键数值与推荐
- 五药难治定义为对CD38单抗、2种蛋白酶体抑制剂和2种免疫调节剂难治。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab and isatuximab, has significantly impacted the management of patients with multiple myeloma (MM). Outcomes of patients with MM refractory to CD38 MoABs have not been described. We analyzed outcomes of 275 MM patients at 14 academic centers with disease refractory to CD38 MoABs. Median interval between MM diagnosis and refractoriness to CD38 MoAB (T0) was 50.1 months. The median overall survival (OS) from T0 for the entire cohort was 8.6 [95% C.I. 7.5-9.9] months, ranging from 11.2 months for patients not simultaneously refractory to an immunomodulatory (IMiD) agent and a proteasome inhibitor (PI) to 5.6 months for "penta-refractory" patients (refractory to CD38 MoAB, 2 PIs and 2 IMiDs). At least one subsequent treatment regimen was employed after T0 in 249 (90%) patients. Overall response rate to first regimen after T0 was 31% with median progression-free survival (PFS) and OS of 3.4 and 9.3 months, respectively. PFS was best achieved with combinations of carfilzomib and alkylator (median 5.7 months), and daratumumab and IMiD (median 4.5 months). Patients with MM refractory to CD38 MoAB have poor prognosis and this study provides benchmark for new therapies to be tested in this population.
引用
- Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019. PMID: 30858549. doi:10.1038/s41375-019-0435-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。